The first integrase inhibitor approved by the US Food and Drug Administration (FDA) was Raltegravir (brand name Isentress), approved on October 12, 2007. Research results published in the New England Journal of Medicine on July 24, 2008, concluded that "raltegravir plus optimized background therapy provided better viral suppression than optimized background therapy alone for at least 48 weeks."
Since integrase inhibitors target a distinct step in the retroviral life cycle, they may be taken in combination with other types of HIV drugs to minimize adaptation by the virus. They are also useful in salvage therapy for patients whose virus has mutated and acquired resistance to other drugs.
Japan,United Kingdom : Shionogi and ViiV Healthcare Announce New Agreement to Commercialise and Develop Integrase Inhibitor Portfolio
Oct 29, 2012; ViiV Healthcare Ltd and Shionogi & Co., Ltd. today announced that they have entered into an agreement substantially revising...
New AIDS drug gives fast results, research shows; Integrase inhibitor, when used in cocktail, almost eliminated HIV in 90% of patients in study.(Main)
Aug 13, 2006; Byline: JIA-RUI CHONG Los Angeles Times An experimental AIDS drug, part of a new class of medicines known as integrase...